Zepatier (elbasvir) is a small molecule pharmaceutical. Elbasvir was first approved as Zepatier on 2016-01-28. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Zepatier's patent is valid until 2031-05-04 (FDA).
|Indication||chronic hepatitis c, hepatitis c|
|Drug Class||Antivirals: NS5A inhibitors|